stockrowYarrow Bioscience, Inc
YARWYarrow Bioscience, Inc’s revenue for fiscal 2025 (year ended December 2025) was $570,000.00, up 13.8% from fiscal 2024.
- Revenue
- +40.6%
- EPS
- +46.0%
- Free cash flow
- +81.6%
Quarter to June 2026, against a year earlier
Follow YARW
Alert me
Yarrow Bioscience, Inc (YARW) EV/Sales
As of 6 November 2026, Yarrow Bioscience, Inc (YARW) trades at a EV/Sales of 118×. Over the past ten years it has ranged from −12.3× (March 2020) to 374× (January 2025); the current reading is higher than 71% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 110× | (62.86%) |
| FY2024 | 295× | 180.08% |
| FY2023 | 105× | 15.36% |
| FY2022 | 91.3× | 417.03% |
| FY2022 | 17.7× | (78.45%) |
| FY2021 | 82.0× | 832.82% |
| FY2021 | 8.8× | 2.90% |
| FY2020 | 8.5× | (58.53%) |
| FY2020 | 20.6× | (11.38%) |
| FY2019 | 23.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 149× | 0.30% |
| Mar 2026 | 148× | 35.25% |
| Dec 2025 | 110× | 18.91% |
| Sep 2025 | 92.2× | (55.03%) |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CMPX Compass Therapeutics, Inc. compare | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| MENS Jyong Biotech Ltd. compare | n/m |
| PDSB PDS Biotechnology Corporation compare | n/m |
| MSLE Satellos Bioscience Inc. compare | n/m |
| CUE Cue Biopharma, Inc. compare | 2.7× |
| SPRB Spruce Biosciences, Inc. compare | 4.9× |
| MOLN Molecular Partners AG Sponsored ADR compare | 9.3× |
| YARW Yarrow Bioscience, Inc | 118× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)